Epilepsy is one of the most common neurological disorders, affecting over 70 million people worldwide. RADAR-CNS researchers have been exploring the use of wearable technology to monitor for, and distinguish between different types of seizures and symptoms, including identifying markers of post-ictal states and where there may be a higher risk of SUDEP (Sudden Unexpected Death in Epilepsy).
This data has the potential to be transformative in future research and treatment, to reduce risks of seizures, inform clinicians and help patients manage their epilepsy. Remote Assessment of Disease and Relapse – Central Nervous System (RADAR-CNS) was a collaborative research programme that explored the potential of wearable devices to help measure and predict clinical outcomes in depression, multiple sclerosis and epilepsy. RADAR-CNS was jointly led by King’s College London and Janssen Pharmaceutica NV, funded by the Innovative Medicines Initiative (a Public Private Partnership established between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Union). It included 22 organisations from across Europe and the US, bringing together experts from diverse fields including clinical research, engineering, computer science, information technology, data analytics and health services.
